Emergent BioSolutions Inc.

NYSE
EBS
Stock
Yield per half year: -38.26%
Dividend yield: 0%
Sector: Healthcare

Company Analysis Emergent BioSolutions Inc.

Download the report: word Word pdf PDF

1. Summary

Advantages

  • Price (6.6 $) is less than fair price (8.67 $)
  • The stock's return over the last year (-29.18%) is higher than the sector average (-47.49%).
  • The company's current efficiency (ROE=-33.67%) is higher than the sector average (ROE=-83.32%)

Disadvantages

  • Dividends (0%) are below the sector average (1.28%).
  • Current debt level 47.76% has increased over 5 years from 34.82%.

Similar companies

Allergan

UnitedHealth Group

Humana

Bristol-Myers

2. Share price and performance

2.1. Share price

2.3. Market efficiency

Emergent BioSolutions Inc. Healthcare Index
7 days -0.5% -9.9% 0.2%
90 days 40.7% -45.7% 15.8%
1 year -29.2% -47.5% 11.6%

EBS vs Sector: Emergent BioSolutions Inc. has outperformed the "Healthcare" sector by 18.31% over the past year.

EBS vs Market: Emergent BioSolutions Inc. has significantly underperformed the market by -40.81% over the past year.

Stable price: EBS is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.

Long period: EBS with weekly volatility of -0.5612% over the past year.

3. Summary of the report

3.1. General

P/E: 18.1
P/S: 0.4837

3.2. Revenue

EPS -3.6
ROE -33.67%
ROA -11.86%
ROIC 7.57%
Ebitda margin 3.96%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Below fair price: The current price (6.6 $) is lower than the fair price (8.67 $).

Price significantly below the fair price: The current price (6.6 $) is 31.4% lower than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (18.1) is lower than that of the sector as a whole (52.65).

P/E vs Market: The company's P/E (18.1) is lower than that of the market as a whole (61.84).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (1.02) is lower than that of the sector as a whole (10.86).

P/BV vs Market: The company's P/BV (1.02) is lower than that of the market as a whole (20.59).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (0.4837) is lower than that of the sector as a whole (4.03).

P/S vs Market: The company's P/S indicator (0.4837) is lower than that of the market as a whole (15.97).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (26.3) is higher than that of the sector as a whole (16.29).

EV/Ebitda vs Market: The company's EV/Ebitda (26.3) is higher than that of the market as a whole (18.41).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Negative and has fallen by -32.49% over the last 5 years.

Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-32.49%).

Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-8.87%).

5.4. ROE

ROE vs Sector: The company's ROE (-33.67%) is higher than that of the sector as a whole (-83.32%).

ROE vs Market: The company's ROE (-33.67%) is lower than that of the market as a whole (42.62%).

5.5. ROA

ROA vs Sector: The company's ROA (-11.86%) is lower than that of the sector as a whole (6.38%).

ROA vs Market: The company's ROA (-11.86%) is lower than that of the market as a whole (23.26%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (7.57%) is lower than that of the sector as a whole (15.07%).

ROIC vs Market: The company's ROIC (7.57%) is lower than that of the market as a whole (9.15%).

6. Finance

6.1. Assets and debt

Debt level: (47.76%) is quite low in relation to assets.

Increasing debt: over 5 years, the debt has increased from 34.82% to 47.76%.

Excess of debt: The debt is not covered by net income, percentage -348.22%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '1.28%.

7.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.

7.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Selling More insider purchases by 100% over the last 3 months.

8.2. Latest transactions

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Emergent BioSolutions Inc.

9.3. Comments